GGrantIndex
Sort

50,496 grants matching lung cancer

In-patient hospice and rapid autopsy to interrogate tumor heterogeneity

$399,554
Udayan Guha · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology

$399,554
K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2024 · CA

Clinical Protocols in the Cancer Signaling Networks Section

$399,554
Udayan Guha · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Cigarette Smoking among American Indian Women Experiencing Intimate Partner Violence

$399,542
Patricia Nez Henderson · Black Hills Ctr/American Indian Health · S06 · FY2018 · GM

Project 1: Effects of unventilated filters on pattern of cigarette use, toxicant exposure and uptake of alternative nicotine products

$399,540
Dorothy K Hatsukami · University Of Minnesota · P01 · FY2017 · CA

Core B: Biomarker and Constituent Core

$399,539
Irina Stepanov · University Of Minnesota · P01 · FY2017 · CA

Genetic Determinants of Oxygen Toxicity

$399,517
Valeria C Culotta · Johns Hopkins University · R37 · FY2011 · GM

Development of Programmable mRNA Circuits for Melanoma Immunotherapy

$399,508
Ryan Sowell · Strand Therapeutics Inc · R43 · FY2021 · CA

An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy

$399,499
Deeksha Saxena · Liquid Biodx Llc · R43 · FY2023 · CA

Reposition and Optimization of Deferiprone for Breast Cancer Therapy

$399,479
Adegboyega Oyelere · Georgia Institute Of Technology · R01 · FY2025 · CA

Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu

$399,448
William Pao · Sloan-Kettering Inst Can Research · P01 · FY2012 · CA

SOUTHWEST ONCOLOGY GROUP

$399,443
Swedish Medical Center, First Hill · U10 · FY2002 · CA

Novel Anti-CCR8 VHH for the Treatment of NSCLC

$399,424
Mauro Mileni · Abilita Bio, Inc. · R43 · FY2023 · CA

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

$399,380
Alice T Shaw · Massachusetts General Hospital · R01 · FY2018 · CA

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

$399,380
Jessica Jiyeong Lin · Massachusetts General Hospital · R01 · FY2021 · CA

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

$399,380
Jessica Jiyeong Lin · Massachusetts General Hospital · R01 · FY2020 · CA

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

$399,380
Alice T Shaw · Massachusetts General Hospital · R01 · FY2017 · CA

Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma

$399,356
Roberto Chiarle · Boston Children'S Hospital · R01 · FY2024 · CA

Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers

$399,346
Richard L. Klemke · Cytonus Therapeutics, Inc. · R41 · FY2020 · CA

Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization

$399,294
Richard J Price · University Of Virginia · R21 · FY2024 · CA

Activation and Regulation of the Understudied Kinome Using MIB/MS Technology

$399,282
Gary L. Johnson · Univ Of North Carolina Chapel Hill · U01 · FY2014 · MH

Training Grant in Lung Cell and Molecular Biology

$399,249
Benjamin D Medoff · Massachusetts General Hospital · T32 · FY2010 · HL

Engineering therapeutic and diagnostic proteins for tumor biomarker mesothelin

$399,232
Sarah J. Moore · Smith College · R15 · FY2015 · CA

c-Myc modulation and its implications in EGFR-targeted cancer therapy

$399,207
Shi-Yong Sun · Emory University · R01 · FY2020 · CA

Shifting the immune infiltrates in osteosarcoma lung metastases with locally targeted CSF-1Ris for combination therapies

$399,187
Sandro R. P. Da Rocha · Virginia Commonwealth University · R21 · FY2021 · CA